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Abstract Fabry disease is a multi-systemic X-linked
genetic disorder which has progressive and deadly con-
sequences for those it afflicts. Fabry disease symptoms are
widely recognized as a substantive burden for affected
males. In comparison, female heterozygotes have tradition-
ally been viewed as relatively symptom-free, though a
debate continues about whether and how much they suffer
with the disease. Previous research suggests that females
with Fabry disease may be triply disadvantaged in health-
care settings owing to: (l) disease rarity, (2) devalued
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carrier status, and (3) gender. The combined effects of these
three factors suggest that female heterozygotes may suffer
substantially with Fabry disease symptoms. A qualitative
analysis of a brief disease-specific questionnaire provides
supportive evidence. The female Fabry disease participants
described experiencing significant synptoms that interfered
with their lives. They also described unsatisSing experi-
ences with healthcare professionals related to disease rarity,
carrier status, and gender. The results of this study
corroborate the suggestion that this triple disadvantage
exists and may preclude appropriate management and
treatment of females with Fabry disease. The role of
healthcare professionals, including genetic counselors, in
remedying this disadvantage is reviewed.
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Introduction
Fabry disease is a multi-systemic X-linked genetic disorder
which has progressive and deadly consequences for those it
afflicts. Symptoms of the disease vary but can include
hypohidrosis (an inability to sweat), angiokeratomas (a
characteristic skin lesion typically of the trunk region of the
body), comea verticillata (a whorl-like pattem of the cornea
which does not impair vision), gastrointestinal problems,
and acute or chronic neuropathic pain @ukuhara et al.
i975; Kahn i973; Ries et al. 2003). The disease causes
progressive damage to multiple body systems, including the
eyes, kidneys, heart, and brain (Brady et al. 2001;
Schiffmann et al. 2001). Commonly, those with Fabry
disease have a foreshortened life owing to complications of
renal failure and cardiovascular or cerebrovascular disease
(Breunig et al. 2003; Desnick et al. 2003; Grabowski and
Hopkin 2003).
Fabry disease symptoms are widely recognized as a
substantive burden for affected males (Ries et al. 2001), but
the debate persists about the extent to which females are
affected by the disease. The presence of sex differences in
disease severity has important implications for management
and treatment since females with Fabry disease may be
marginalized, dismissed, and/or igrored in current medical
practice. Based on a quantitative survey of the pain
associated with Fabry disease, we previously suggested
that females with this disease may be triply disadvantaged
in healthcare settings due to: (1) disease raity, Q) devalued
carrier status, and (3) gender (Gibas et al. 2006). The
combined effects of these three factors suggest that females
may suffer substantially with the symptoms of Fabry
disease.
Disease Rarity
The disadvantage of disease rarity within a healthcare
system is evident: few medical health professionals will
encounter a person with a rare disease. As a consequence,
the probability of a misdiagnosis or delayed diagnosis
increases, often with harmful consequences. Fabry disease
is no exception with an estimated prevalence of 1:40,000-
117,000 in the general population (Desnick et al. 2003;
Kahn i973). Unless a family history has been identified,
Fabry disease may be misdiagnosed as a more common
disease that exhibits similar symptomatology @esnick et
aL 2043). Thus, individuals suffering with Fabry disease are
often not accurately diagnosed until adulthood, years after
the initial onset of symptoms of the disease (Brady et al.
2001; Hopkin et al. 2003). The average age at Fabry
disease diagnosis is 29 years for males (Desnick et al.
2AA3), years after disease pathology has significantly
progressed and potentially darnaged multiple bodily sys-
tems (Brady et al. 2001; Schiffinann et al, 2001). Although
the onset of Fabry disease symptomatology in females may
be comparable to males (Ries et al. 2003), the average
delay in diagnosis is 16.3 years from the onset of symptoms
for females, compared with an average of 13.7 years for
males (Mehta et al, 2004).
Devalued Carrier Status
The second potential disadvantage-that of a devalued
carrier status-is specific to sex-linked diseases like Fabry
disease. Female heterozygotes have one mutant and one
non-mutant X chromosome-thus establishing their carrier
status. This has perpetuated the impression that females
with Fabry disease are clinically affected to a lesser degree
than males. Female Fabry disease patients have been
described as asymptomatic (Chowdhury and Holt 2001;
Doi et al. 2003) or as exhibiting intermittent and mild
symptoms of the disease @oi et al.2{\A3; Ro et al. 1999).
However, approximately lo/o of females with Fabry disease
were reported to have symptoms as severe as males
@aehner et aL 2A03). Neuropathic pain, a frequent sequela
of Fabry disease, has been reported to be experienced by
l0%o of female heterozygotes, and when it occurs, it is
alleged to be experienced only intermittently, or only under
"certain circumstances" (Chowdhury and Holt 2001).
However, the results of empirical research are beginning
to challenge the view of females as asymptomatic or
marginally affected. Fabry disease has been shown to
account for a large number of symptomatic female carriers
(Pastores and Lien 2002). By contrast, female carriers of
another X-linked lysosomal storage disease, Hunter disease,
are never symptomatic unless a coincidental genetic defect,
such as X-autosome translocation, causes preferential
expression of a mutated gene for Hunter disease. The
nature of Fabry disease symptoms may be comparable in
females and males (Ries et al. 2003), with 60-70% of
heterozygote females expressing traditional symptoms of
the disease (Bennett et al. 2002). In a sample of female
Fabry disease patients MacDermot and colleagues (2001)
reported that 30yo manifested multiple serious symptoms of
the disease, with 70% experiencing significant neuropathic
pain, a more credible prevalence than previously reported in
the literature. The normal lifespan for females is also
similarly foreshortened by Fabry disease (Pastores and Lien
2002). These recent findings imply that the severity and
pervasiveness of Fabry disease manifestation in females
may be greater than previously thought @aehner et al.
2003).
Females in Healthcare
The third disadvantage for female Fabry disease patients is
their gender. Gender inequality is a major barrier to
achieving quality healthcare (Gijsbers van Wijk et al.
199i). Although women account for the greater proportion
of healthcare users (Gijsbers van Wijk et al. 1991), male-
derived models of pathology and treatment dominate
medicine @facDougall 2A02) and bias the provision of
healthcare services for females. Disparities in ffeatment
between the sexes (i.e., the "gender gap") have been
consistently identified for lung, heart, and kidney disease,
which are predominantly perceived as "rnale diseases."
Evidence also suggests that females are referred less often
for diagnostic or therapeutic interventions and are ffeated
less aggressively than men (Gijsbers van Wijk et al. i99l).
Differences in treatment between males and females do not
disappear when conffolling for other confounding variables
such as age, disease severity, and risk factors (Gijsbers van
Wijk et al. 1991). To date there are few data that directly
address the issue of the provision of healthcare services for
females with Fabry disease.
Each ofthe above identified factors: (1) disease rarity,(2)
devalued carrier status, and (3) gender, have been shown to
impact the quality of healthcare provided and received by
patients. The aim ofthe present paper is to examine verbatim
reports regarding pain experiences from women with Fabry
disease. The data were collected in an earlier studv (Gibas
et al. 2006), but not previously published.
Methods
The qualitative results reported in the present paper were
derived from a pilot study of the neuropathic pain
experiences of males and females formally diagnosed with
Fabry disease (Gibas et aL.2006). The study received ethics
approval from the Research Ethics Board at the Hospital for
Sick Children and the Human Participants Review Com-
mittee at York University (Toronto, Ontario, Canada).
Participants
The participants included in the present study were female
Fabry disease patients who were members of a Fabry
disease support group (the Fabry Support & Information
Group or FSIG; rv'ivw.fabry.org). At the time of completion
of this research, the FSIG was comprised of 552 members
(221males,230 females, and 101 sex not indicated). Of the
552 members, 454 identified themselves as Fabry disease
patients, and 98 as family members or of a non-specified
relationship.
Measures
The data for this sfudy were collected through a brief
disease-specific questionnaire designed to assess patient
perceptions of the symptoms of Fabry disease, primarily
neuropathic pain. The following fwo open-ended questions
were included on the survey, from which the present results
were derived:
(1) What aspects of your life are most affected by Fabry-
related pain?(2) How could your doctor get a better idea of the pain/
discomfort you have?
Procedure
On April 28th and 30th, and May 6th and 9th, 2003, the
questionnaire was made available electronically on the
discussion page of the FSIG. In order to ensure that only
Fabry disease patients completed the questionnake, parlic-
ipants were required to print out the form, complete it by
hand, and mail it to the FSIG. A member of the FSIG
reviewed the questionnaires, stripped them of any identify-
ing information and mailed the anonymous forms to the
researchers. To generate additional Fabry disease patient
responses, a copy of the questionnaire was mailed to the
552 members of the FSIG.
Data Analysis
The written responses derived from the two open-ended
questions were analyzed with the help of QSR NVivo
(Windows, release 2.0, Doncaster, Victoria, Australia). For
the descriptive analyses, an inductive coding technique was
used to analyze the data (Miles and Huberman 1994). With
this technique, themes arise from the raw data, rather than
being deductively coded from a pre-determined theory or
methodology (Miles and Huberman 1994). A strength of
qualitative methodology is the process of induction,
whereby themes emerge to provide grounded theory or a
hypothesis, rather than the reverse (Morse 1991).
Using the process of induction, the open-ended, written
responses from the female Fabry disease survey participants
were independently reviewed by two coders (AG and JK)
line by line, and divided into "meaning units" (Thomas
i993), to generate emergent categories. The two analysts
independently coded the same data and developed their
own coding structure. The preliminary coding schemes
derived individually from each analyst were compared.
There was broad overlap between the two analysts' coding
schemes, and slight discrepancies were resolved through
discussion and consensual agreement. The result of the
discussion was the formation of a coherent coding
framework that attempted to be most representative of the
data. Accordingly, the data were subsequently recoded to a
unified coding structure.
After this first revision, the two analysts met a second
time to finalize the coding framework. The two analysts
concurred that the finalized coding framework was appro-
priate, incorporating the breadth and specificity of catego-
ries inherent in the open-ended responses.
Results
Demographic variables for the female Fabry disease
participants in this study (n:51) indicate that the mean
age of the participants was 45.9 years old (SD:13.5; range:
22-78 yearc). The mean age at diagnosis ofFabry disease
was 31.1 years (SD:14.0; range: 2-57 years). The
participants resided primarily within the United States,
although a minority was from Carada and Europe. More
detailed information regarding the Fabry disease status and
quantititative pain measures of this sample is provided in a
previously published article (Gibas et al. 2006). No other
demographic information was collected.
Ernergent Themes
From the qualitative analysis, in total, seven primary
themes were derived from the two open-ended survey
questions (Question 1 included four main themes and
Question 2 included three main themes). Overall, five
themes were considered relevant for the purposes of this
research and were analyzed in further detail (see Tables 1
and 2). Additional themes that were not relevant to the
current purpose were not included in the results. The data
for each theme are presented below, with participanL data
presented in quotations, and the sample size (n) is provided,
where available.
Question 1: What aspects of your life are most aflected by
Fabry-related pain?
Theme 1: Defining Fabry Disease Pain
The comments by participants reflect three critical dimen-
sions of neuropathic pain: intensity (n:9), quality (n:ll),
and chronicity (n:6).These dimensions did not appear to
be mutually exclusive, as evident by one female partic-
ipant's comment:
"The pain at its worst is unbearable, relentless and
excruciating. It is stabbing, throbbing, constant bum-
ing sensations that do not stop until they have run their
course. it could be minutes or days. ... The intensity
Table I Selected Themes for Question I : What Aspects of Your Life
are most Affected by Fabry-related Pain?
Main theme Definition Sub-theme (n)
Table 2 Selected Themes for Question 2: How Could your Doctor get
a Better ldea of the Pain/Discomfort You Have?
Main theme (r) Definition Sub-Theme (z)
Theme 3: Level of
satisfaction with
physician assessmenl
and management of
Fabry disease pain
Theme 4:
Misconceptions
regarding females
with Fabry disease
Expressed level of
satisfaction with
physician assessment
and management of
Fabry disease pain
Comments regarding
encounters with
healthcare
professionals that
involved
misconceptions of
female Fabry
disease patients
Comments involving
female Fabry
disease patients'
perception of
needed changes
and remedies
Satisfaction (z=8)
Dissatisfaction (r=8)
Misconceptions
regarding disease
rat''ty (n:4)
Misconceptions
regarding
devalued carrier
status (r:6)
Misconceptions
regarding gender
(n=2)
Improved medical
ttainhg (n:24)
Improved patient-
physician
communication
(n=6)
Theme 1: Defining
Fabry disease pain
Theme 2: Fabry
disease pain
interference with
multiple life
domains
Comments
regarding critical
dimensions of
neuropathic pain
Comments
highlight life
domains that
are impacted by
Fabry disease
Pain
Intensity of pain (r:9)
Qualiry of pain (n:11)
Chronicity of pain (r:6)
Physical/bodily functioning
(n=40)
Occupational fu nctioning
(tt=11)
Relationship fu nctioning
(zr: I 5)
Emotional functioning
(n=28)
Theme 5: Proposed
remedies
z refers to number of comments
of the pain diminishes to a constant pain, but the
stabbing feeling is gone. There is no way to describe
how this constant pain day in, day out eventually
begins to affect your overall health and attitude."
(Participant 025)
Descriptions from women with Fabry disease are
suggestive of the intensity of their pain experiences: "this
pain was and still is excruciating. The pain is so intense that
it overcomes me" (Participant 2385) and "this pain I have
experienced is so deep in my bones" @articipant 8521).
Female participants (z=9) reported "severe," "intense,"
"extreme" or "excruciating" Fabry-related pain @artici-
pants 040, 025, 2385, respectively). One comment, in
particular, highlights the potency of one female partici-
pants' lived pain experience:
"The episodes of pain in hands and feet are impossible
to describe because the pain is so personal and out of
control when it comes...The severe abdominal cramp-
ing is a sudden onset pain that is scary and something
you're not sure you can survive. It actually feels like it
might kill you [sic] many times I have passed out-I
just hope and pray if I pass out the pain will be over
when I come back ... if I come back." (Participant 040)
Pafticipants provided vivid descriptors of the quality of
pain they experience (n:11). Their descriptions are
indicative of the burning and tingling that is characteristicn refers to numbef of comments.
of neuropathic pain in general. For example, the pain "...
felt as though my nerve endings were short circuiting or
on fire" (Participant 2385) and "...you want to get away
from the buming and tingling and you can't" (Participant
040). Other qualities of neuropathic pain reported were "It
is stabbing, throbbing" (Participant 025) and "once the
stabting pain subsides, my hands and feet still burn ...
but do not feel like they are flaming anymore" (Participant
2385).
Participants reported experiencing their disease-related
pain as being constant or "relentless" (Participanl 025; n:
6). The chronicity ofthe neuropathic pain ofFabry disease
was captured by such statements as: "never a day goes by
that I don't exhibit some pain" (Participant 014) and "I am
in pain in one form or another most of the time"
(Participant 8993). Some of the female participants have
dealt with the pain of Fabry disease for a long period of
time. One 32-year-old participant (Participant 2385) noted
that she has lived with "incredible pain" in her extremities
since the age of two. She continued, stating "I long for the
day that I no longer have pain and can do the things that I
long to do... I cannot think of anything but when will it
stop."
Of interest, not all respondents reported that neuropathic
pain was a problem. A minority endorsed no, or minimal,
Fabry disease pain experiences (n:4). The responses
indicated "rare" (Participant 040), "very few" (Participant
060), or "no real" (Participant 079) Fabry-related pain
symptoms. Or, as Participant 5296 reported, "I don't have
intense pain. However mainly bothersome symptoms [sic]."
Theme 2: Fabry Disease Pain Interference with Multiple
Domains of Life
The female participants' responses highlighted the multi-
tude of life domains that have been impacted by Fabry
disease pain (e.g., "My life is most affected by the pain and
fatigue in my daily work, family, recreation, and interaction
with friends" Participant 057 or "All aspects of my life have
changed due to Fabry related pain and other symptoms"
Participant 8993). According to the participants, life was
significantly affected in four major domains, including:
physical/bodily functioning (n:40; e.g., "Some days it is
even hard to hold a pen to write" Participant 006),
occupational functioning (n:11; e.9., "I gave up a full
time job ... because of the pain, fatigue" Participant 057),
relationship functioning (n:15; e.g., "When I get the
burning in my hands and feet. I cannot function at all.
And it's a hard thing when you hurt so badly you can't even
hold your own child" Participant 069), and emotional
functioning (n:28; "The stress and frustration from day to
day problems and pain is enough to put my emotions on a
loop!" Participant 066).
Question 2: How could your doctor get a better idea of
the pain/discomfort you have?
Theme 3: Level of Satisfaction with Physician Assessment
and Management of Pain
Eight women with Fabry disease commented that they were
satisfied with their care and management by physicians (e.g.,
"I personally feel like my physicians do understand the
pain" Participant 8521). Typically, these women received
healthcare at specialized treatment and research centres
(e.g., the National Institutes of Health). Satisfaction was
equated with patient-perceived level of physician knowl-
edge of Fabry disease. For example, "My doc has done
his best to learn all he can about our disease..."
(Panicipant 055) and "My Dr. fortunately has a very
good knowledge of Fabry's. He has read all the material
provided by [the drug company] and everything on the
Intemet, plus all the information I and other patients have
dug up for him" (Participant 0ll). Satisfaction was also
equated with physician understanding and awareness of
the disease. This was evident through statements like the
following:
"Personally my physicians seem to have quite an
understanding .... A physician canjust do so much-
he can not take the disease away ... I am very
fortunate to work with a physician ... who is very
much aware of Fabry's. Also, I have a wonderful
nephrologist who has done much studies [sic] on this
disease. They both work extremely hard and show
much concem for me." @articipant 052)
Additional conrnents included, *I think Fabry doctors
have a good idea of the characteristic pain" (Participant
012), "My doctors are well aware of the pain I'm in..."
(Participant 016) and "I personally feel like my physicians
do understand the pain..." (Participant 8521).
Despite the satisfaction with healthcare expressed by
some participants, other responses indicated an explicit
general dissatisfaction with physicians (n=8). For example,
one participant stated "I was diagnosed 25+years ago. My
experience with most doctors has been that most of them do
not understand the pain/discomfort of Fabry" (Participant
057). Five participants claimed that to fully understand the
disease, physicians must experience the disease pain and
discomfort themselves: "The only way I know is if they
themselves fphysicians] experienced this excruciating pain
and buming" (Participant 014), "If they [physicians] could
experience Fabry-related pain for just t hour they would get
a clear picture" (Participant 057). For the remainder,
dissatisfaction was expressed through refutation that physi-
cians (or anyone) could understand the pain of Fabry
disease-('Personally, I don't think anyone could get an
idea of the extent of the pain suffered with people who have
Fabry disease" @articipant 006).
Theme 4: Misconceptions Regarding Females with Fabry
Disease
Almost a quarter of the sample of the females with Fabry
disease (n=12) reported encounters with medical health
professionals that were suggestive of misconceptions
regarding (1) disease rarity (i.e., ignorance of the disease
and that females may be affected), (2) devalued carrier
status (i.e., the dismissal of females because of their carrier
status), and (3) gender (i.e., disbelief of female pain and
other Fabry disease symptoms).
Misconception #l: Disease Rarity
The rarity of the disease in the general population may
contribute to the misconception that women with Fabry
disease may be adversely affected by symptoms of the
disease. Responses ofthe participants in this study suggest
that this misconception has continued to prevail, despite
increasing recognition in the literature ofthe prevalence of
women experiencing Fabry disease symptoms. For exam-
ple, one parlicipant commented that "... fPhysicians need]
a better understanding of the disease and the fact that
women are affected" (Participant 028). Another participant
felt that the onus was on her to educate her physician about
the disease in order to receive appropriate care: "I need to
better describe my pain to her [her physician], and give her
more information regarding the impact of Fabry disease on
women" (Participant 041).
Misconception #2: Devalued Carrier Status
The traditional misconception that women heterozygous for
Fabry disease are asymptomatic or minimally symptomatic
for the disease was evident in the participants' reports. For
example, one participant commented "... the 'can'ier' label
has been an exffeme injustice to Female Fabbers" (Partic-
ipant 065). Another commented,
"It's also a problem to know I have these major
complaints and discomfofts and most people still stand
by the fact that women don't have Fabry-it's
upsetting! " (Parricipant 066)
Study participants wanted physicians to recognize the
presence and extent of their disease-related symptoms:
"Accept the fact that even though I am a carrier and do
not have obvious kidney problems, I do have other
aspects of the disease that are very debilitating. Like
the severe abdominal cramping and diarrhea episodes
that are particularly associated with overheating."
(Participant 040)
One participant acknowledged that not all healthcare
professionals adhere to the 'carrier' status misconception:
"Even though I was diagnosed with Fabry [disease], I
have been told over and over that I am a carrier and
am asymptomatic and the medical problems are not
from any particular disease. There are some that
listen." (Participant 057)
Misconception #3 : Gender
Often when an examination reveals no objective evidence
of disease, females are more likely than males to be
regarded by physicians as less credible (Malterud 2000).
The symptoms may be ascribed a psychosomatic origin. As
was evident in this study, previous diagnoses given to
female Fabry disease patients included psychiatric disor-
ders; in fact, one patient reported that "they [healthcare
professionals] think we're crazy" (Participant 069). Further
corroborating this view, another study participant com-
mented, "over the years I have been called a hypochondri-
ac, a psychotic woman, and many other titles. Even now,
because tle doctors in my area know little or nothing of
these problems" (Participant 014). A third participant
stated, "Fabry's [sic] is particularly 'misunderstood' and
mistaken for hypochondria due to the fact that much of
what causes us to be sick can't be seen or observed"
(Participant 004).
If the symptom presentation by females is not entirely
dismissed by healthcare professionals, it is often considered
to be less significant than similar symptom presentations by
their male counterparts, as exemplified in the following
passage:
"His fher physician's] very first comment after the
Fabry diagnosis was "Well, you are lucky ... you're not a
rnan...you'd have problems...women don't have any
problems!" He also did not even know how to pronounce
it! Now he just avoids me and placates me and leaves it
up to other doctors and NIH!" (Participant 065)
The diagnosis of a male relative with Fabry disease was
found to provide sufficient evidence for a diagnosis of the
disorder in females-despite long-standing suffbring and
medical complaints by the affected females. For example,
one participant commented "... many days I am so
depressed because for years the doctor told me that it was
all in my head. Once my son was diagnosed life has gotten
a little better" (Participant 051).
Theme 5: Proposed Remedies
Female Fabry disease participants reported that few
physicians were available to appropriately treat the disease:
"When I find a doctor in this area who knows more about
Fabry's than I do, I will definitely be impressed and claim that
doctor as my own. However, at this point, I'm still looking"
(Participant 060). One female participant recounted an
unprofessional encounter with her physician when she asked
about his medical knowledge of Fabry disease:
"I once asked a doctor what he knew about Fabry's
disease. His response to me was 'Nothing, I guess I
must have skipped class that day.' Qrleedless to say, I
never saw that Dr. again!)." (Participant 060)
Thus, overall, the majority of female participants (n:24)
proposed a need for improved medical education and/or
training of medical health professionals regarding Fabry
disease. Examples of such comments frorn participants
include: "medical schools need to be aware of this
condition" (Participant 006), "... fdoctor's should] try to
learn more about Fabry's and the ugly things this disease
causes and makes us feel" (Participant 027), and "the
doctor's [sic] need more information on Fabry's. Most
physicians say they have never heard of the disease"
(Participant 043).
Additionally, female participants (n:6) acknowledged
that at least part of the responsibility for the patient-
physician relationship involved improved communication
on their part. For example, one participant wrote "I need to
better describe my pain to her" (Participant 041) and
another, "Verbally explain, to the best of my ability, the
pain that I'm experiencing" (Participant 045). An informa-
tion sheet or a daily pain joumal were patient-initiated
methods suggested to facilitate physician understanding of
Fabry-related pain.
Discussion
Fabry disease pain is notably distinctive (Scott et al. 1999),
and purportedly defies description: "The episodes of pain
in hands and feet are impossible to describe because the
pain is so personal and out of control when it comes"
(Participant 040). However, in examining the responses to
a survey on neuropathic pain symptoms of Fabry disease as
part of a previous study (Gibas et aL 2A06), the repetition of
content by many of the female Fabry disease participants
suggests some agreement and consistency of experience;
thus, this permits a tentative qualitative description of Fabry
disease pain. The descriptions of pain symptoms provided
by the study participants conoborate previous research
reporting that females heterozygous for Fabry disease
experience significant pain (MacDermot et al. 2001; V/ang
et aL 2AA7\.
Moreover, the pain of Fabry disease influences an
afflicted individuals' capacity to perfonn what are typically
perceived as normal, everyday physical tasks (e.g., hand-
writing, holding hands with a partner). The comments by
the female participants suggest that Fabry disease impairs
social, occupational, and other important areas of function-
ing. This is consistent with more recent research (Wang et
al. 2007), which suggests that quality of living is hampered
in females with Fabry disease.
The personal descriptions ofsignificant pain experiences
combined with an apparent limited understanding on the
part of physicians provides evidence that females with
Fabry disease present a special problem to the healthcare
profession. Upon closer examination of the verbatim
reports, the results of the present study indicate that some
females with Fabry disease had experiences of being
ignored, dismissed, and disbelieved by healthcare profes-
sionals. Sufficient concem, and now preliminary evidence,
has been adduced to support the suggestion that females
with Fabry disease may be triply disadvantaged in current
healthcare systems. The combination of (l) disease rarity,
(2) devalued carrier status, and (3) gender appears to have
contributed to this unfortunate disadvantage. Dated mis-
conceptions of Fabry disease symptomatology and its effect
on women persist. It is important to note that any
impediment-whether intentional or not-to the diagnostic
process will delay vital treatment and management of Fabry
disease. Given the progressive nature of this disease, these
misconceptions may contribute to the foreshortening of life
for females with Fabry disease.
The current healthcare system may have served as a
conduit for these misconceptions, thereby facilitating this
barrier to diagnosis and treatment. In her seminal work on
female patients with medically unexplained illnesses (e.g.,
fibromyalgia), Malterud (2000) described five common
'traps' healthcare professionals fall into that pelpetuate
delivery of suboptimal medical care. Of the five traps, three
overlap with the experiences reported by the females in this
study suffering from Fabry disease: the universalistic trap
(i.e., considering only a single cause of symptoms for a
group of patients), the psychosocial trap (i.e., ascribing
symptoms that defy explanation to mental illness), and the
gender trap (i.e., harboring different expectations for males
and females). These traps help to explain how female Fabry
disease patients rnay be triply disadvantaged in healthcare
settings, resulting in the potential dismissal of their disease
symptoms. In general, the traditional view within the medical
community of females as sirnply disease can'iers may have
contributed to the dismissal of these Datients'svmDtoms.
First, the dismissal of Fabry disease symptorns by health-
care professionals may be likened to Malterud's (2000)
universalistic trap. This occurs when a single condition is
incorrectly assigned to all patients with similar character-
istics; in this case, all females heterozygous for Fabry disease
are seen as being asymptomatic, despite research and clinical
evidence to the contrary. As Malterud suggests,
"The physician who holds a single favorite under-
standing and solution of unexplainedness bears the
risk of objectifying a diverse group of suffering
persons by tuming them into a supposedly uniform
crowd of 'these women."' O. 608)
One consequence of the universalistic trap is that female
patients may be required to continually contest the reality of
their disease experience (Eccleston et al. 1997). As
indicated by Participant 065, simply "...the 'carrier' label
has been an extreme injustice to Female Fabbers." Trust
befween patient and physician, a necessary element in a
medical setting, becomes compromised (Diarnond and
Grauer 1986).
As was evident in this study, previous diagnoses given to
female Fabry disease patients included psychiatric disor-
ders, likely because they were seen to exhibit "medically
unexplained" symptoms (Malterud 2000). When faced with
the subjective and unexplainable symptoms of Fabry
disease, the physician may fall into the psychosocial trap
and apply a default diagnosis of a psychiatric disorder
(Malterud 2000). The comment from Participant 069 aptly
highlighted this trap-"they [healthcare professionals] think
we're crazy." Indeterminate symptom presentation is more
often interpreted as psychosocially-based when the patient
is female, rather than male (Malterud 2000).
Malterud (2000) further describes a gender trap, which is
obviously applicable to this study, exemplified by a female
with Fabry disease being told by a healthcare professional
that she was "lucky" that she was not a man diagnosed with
Fabry disease ("Well, you are lucky ... you're not a man...
you'd have problems...women don't have any problems!"
Participant 065). Ix a sample of female chronic disease
sufferers, it has been noted that,
"Even today, women's health (or illness) experiences
appear full of contradictions...; they described how
doctors questioned the very reality of their symptoms
and sometimes misdiagnosed them because symptoms
were interpreted by medical practitioners as not being
serious." (Kralik et al. 2001, p. 600)
Women predominantly comprise the so-called 'hearl-
sink patients' (Malterud 2000), or problem patients that are
bothersome to physicians. Often, these patients may be
dismissed as attention-seeking (Singh et al. 1981). For
women with Fabry disease encountering healthcare profes-
sionals, the gender trap appears to be prominent. The
comments provided by the female participants in this
research provide evidence that a gender bias appears to
have influenced the approach of some physicians to women
with Fabry disease. Gender bias in the medical profession
affects subsequent diagnosis and ffeatment (Malterud 2001).
Of course, despite the presence of these identified traps, i!
would be naive to assign sole blame to the healthcare
profession for the triple disadvantage of female Fabry disease
patients. However, the recognition and avoidance of these
traps in medical practice would help to improve care of
women with Fabry disease, by impacting physicians' "ffeat-
ment protocols and their prescription pads" (MacDougall
2002, p. 848). In addition, genetic counselors can assist
physicians in the recognition of at-risk females when a
familial male is affected, based on pedigree. It may also be
important for genetic counselors-who are aware that
women with Fabry disease are often symptomatic-assist
their diagnosed patients in educating their own primary
care providers about the disease. Genetic counselors,
particularly those that specialize in metabolic clinics, could
also advocate within healthcare on behalf of women with
Fabry disease (e.g., provide educational seminars to other
healthcare professionals). The facilitation of referrals of
female Fabry disease patients to pain management special-
ists and other complementary therapists (e.g., acupunctu-
rists) who are knowledgeable about the disease rnay also
help ease debilitating pain symptoms. Lastly, genetic
counselors routinely work with individuals diagnosed with
a rare disease, like Fabry disease, and as such can provide
appropriate psychosocial support and resources to assist
those patients. With these combined efforts, a decline in
the marginalization of women with Fabry disease within
the current healthcare system may be realized.
It must be noted that some women in the present sample
were satisfied with their treatment and had physicians who
were knowledgeable and kept up to date with developments
in Fabry disease research. These women primarily received
aare aI specialized treatrnent and research centres (e.g.,
National Institutes of Health) where misconceptions and
ignorance are typically less prevalent. But, for the majority
of females with Fabry disease, the misconceptions have an
obvious detrirnental impact when seeking effective treat-
rnent in non-specialized medical settings.
Study Limitations
There are sorne limitations of this study. First, the results
were derived from two broad questions about pain on a
survey primarily targeting neuropathic pain and other
symptomatology of Fabry disease. Since the sutvey
questions did not directly or explicitly ask participants
to provide experiences related to a triple disadvantage in
the healthcare, the results may not capture the partic-
ipants' experiences fully. In addition, the results were
derived from a written survey, in which contextual
information is lirnited. Personal interviews with the target
sample (i.e., personal interviews or focus groups with
women with Fabry disease) may provide a greater
breadth and depth of knowledge regarding the issue at
hand. Lastly, the sample size from which the comments
were derived was small and from one source (a Fabry
disease support group). Thus, the extent to which the
results may be generalizable to the population of women
suffering from Fabry disease is unknown.
Nevertheless, it is important to note that almost one-
quarter of the sample of female Fabry disease patients
spontaneously described adverse encounters with health-
care professionals on questions unrelated to this issue.
This suggests that a significant problem exists. The con-
tent and consistency in responses also strongly suggests
that these women were overlooked, dismissed, and/or
ignored when seeking medical treatment. It is possible
that the one-quarter prevalence found in this study is an
underestimate of the triple disadvantage experienced by
female Fabry disease patients. Research that directly
targets this issue, by explicitly asking women about their
healthcare experiences, may provide a more reliable
estimate of the prevalence of this issue. Further research
in this area is needed.
Conclusions
Taken together, the results ofthe present study indicate that
the majority of this sample of women is living with
significant, life-altering neuropathy. In addition, women
with Fabry disease may be triply disadvantaged in health-
care settings, owing to their (l) devalued carrier status, (2)
gender, and (3) disease rarity. To remedy this triple
disadvantage, genetic counselors can play a critical role in
increasing awareness of this triple disadvantage in health-
care settings. In addition, it is essential for healthcare
professionals to examine the delivery of their care contin-
ually and to ensure that commonplace 'traps' are not
entrenched in their practice. Rather than being dismissive, it
is important for healthcare professionals to conduct a closer
examination of women presenting with an assortment of
ambiguous symptoms. For females with undiagnosed Fabry
disease, this thorough examination may result in medical
treatment and rnanagement that is critical in offsetting the
debilitating progression of the disease.
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